@article{MTMT:34852892,
	title = {Long-term outcomes after endoscopic removal of malignant colorectal polyps. Results from a 10-year cohort},
	url = {https://m2.mtmt.hu/api/publication/34852892},
	author = {Fábián, Anna and Bor, Renáta and Vasas, Béla and Szűcs, Mónika and Tóth, Tibor and Bősze, Zsófia and Szántó, Kata Judit and Bacsur, Péter and Bálint, Anita and Farkas, Bernadett and Farkas, Klaudia and Milassin, Ágnes and Rutka, Mariann and Resál, Tamás and Molnár, Tamás and Szepes, Zoltán},
	doi = {10.4253/wjge.v16.i4.193},
	journal-iso = {WORLD J GASTROINTEST ENDOSC},
	journal = {WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY},
	volume = {16},
	unique-id = {34852892},
	abstract = {Choosing an optimal post-polypectomy management strategy of malignant colorectal polyps is challenging, and evidence regarding a surveillance-only strategy is limited.To evaluate long-term outcomes after endoscopic removal of malignant colorectal polyps.A single-center retrospective cohort study was conducted to evaluate outcomes after endoscopic removal of malignant colorectal polyps between 2010 and 2020. Residual disease rate and nodal metastases after secondary surgery and local and distant recurrence rate for those with at least 1 year of follow-up were investigated. Event rates for categorical variables and means for continuous variables with 95% confidence intervals were calculated, and Fisher's exact test and Mann-Whitney test were performed. Potential risk factors of adverse outcomes were determined with univariate and multivariate logistic regression models.In total, 135 lesions (mean size: 22.1 mm; location: 42% rectal) from 129 patients (mean age: 67.7 years; 56% male) were enrolled. The proportion of pedunculated and non-pedunculated lesions was similar, with en bloc resection in 82% and 47% of lesions, respectively. Tumor differentiation, distance from resection margins, depth of submucosal invasion, lymphovascular invasion, and budding were reported at 89.6%, 45.2%, 58.5%, 31.9%, and 25.2%, respectively. Residual tumor was found in 10 patients, and nodal metastasis was found in 4 of 41 patients who underwent secondary surgical resection. Univariate analysis identified piecemeal resection as a risk factor for residual malignancy (odds ratio: 1.74; P = 0.042). At least 1 year of follow-up was available for 117 lesions from 111 patients (mean follow-up period: 5.59 years). Overall, 54%, 30%, 30%, 11%, and 16% of patients presented at the 1-year, 3-year, 5-year, 7-year, and 9-10-year surveillance examinations. Adverse outcomes occurred in 9.0% (local recurrence and dissemination in 4 patients and 9 patients, respectively), with no difference between patients undergoing secondary surgery and surveillance only.Reporting of histological features and adherence to surveillance colonoscopy needs improvement. Long-term adverse outcome rates might be higher than previously reported, irrespective of whether secondary surgery was performed.},
	keywords = {LONG-TERM; SURVEILLANCE; OUTCOMES; endoscopic removal; Malignant colorectal polyps; T1 tumor},
	year = {2024},
	eissn = {1948-5190},
	pages = {193-205},
	orcid-numbers = {Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szűcs, Mónika/0000-0002-8791-9452; Szántó, Kata Judit/0000-0003-0749-5061; Bacsur, Péter/0000-0002-8534-0068; Bálint, Anita/0000-0002-3624-896X; Farkas, Klaudia/0000-0003-0599-182X; Milassin, Ágnes/0000-0001-6902-8915; Rutka, Mariann/0000-0003-2360-7836; Resál, Tamás/0000-0002-3842-9094; Molnár, Tamás/0000-0002-4913-7599; Szepes, Zoltán/0000-0002-9466-8719}
}

@article{MTMT:34828644,
	title = {Az anémia etiopatológiája, diagnózisa és kezelése gyulladásos bélbetegségekben [Etiopathology, diagnosis, and management of anaemia in inflammatory bowel disease]},
	url = {https://m2.mtmt.hu/api/publication/34828644},
	author = {Resál, Tamás and Molnár, Tamás},
	doi = {10.33570/CEUJGH.10.1.13},
	journal-iso = {CENT EUR J GASTRO HEPATOL},
	journal = {CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE},
	volume = {10},
	unique-id = {34828644},
	abstract = {Az anémia az egyik leggyakoribb komorbiditás gyulladásos bélbetegeknél (IBD), amelynek a hátterében leggyakrabban a vasháztartás zavara áll. Bár az anémia prevalenciája kifejezetten magas, és az életminőséget is jelentősen rontja, a pontos etiológia tisztázása és a kezelés is gyakran elmarad IBD-ben. Jelen összefoglaló közlemény célja, hogy bemutassa az anémia epidemiológiai adatait, segítse a fennálló vérszegénység etiopatológiai tisztázását, és ezáltal segítse a megfelelő terápia választását az anémia és a vasháztartás rendezésére.},
	year = {2024},
	eissn = {2415-9107},
	pages = {13-17},
	orcid-numbers = {Resál, Tamás/0000-0002-3842-9094; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34828410,
	title = {Insights into treatment of complex Crohn's perianal fistulas},
	url = {https://m2.mtmt.hu/api/publication/34828410},
	author = {Norčič, Gregor and Smrekar, Nataša and Marković, Srđan and Barišić, Goran and Kiudelis, Gediminas and Paužas, Henrikas and Molnár, Tamás and Szijártó, Attila and Šerclová, Zuzana and Roblek, Tina and Uršič, Viktor and White, Ian},
	doi = {10.1186/s12919-024-00291-4},
	journal-iso = {BMC PROCEEDINGS},
	journal = {BMC PROCEEDINGS},
	volume = {18},
	unique-id = {34828410},
	abstract = {Complex perianal fistula is a common complication of Crohn's disease (CD) which leads to negative impact on patient's quality of life. Successful management of the disease requires a multidisciplinary approach, including a gastroenterologist and a colorectal surgeon, applying combined surgical and medical therapy. One of frequently practiced surgical procedures is seton placement in the fistula tract, which is used to control perianal sepsis and drain the fistula, while preventing recurrent abscess formation.Darvadstrocel, a suspension of expanded, allogeneic, adipose-derived, mesenchymal stem cells, is safe and effective for treatment-refractory complex perianal fistulas in patients with Crohn's disease. Following approval of darvadstrocel, the INSPIRE registry is being conducted in order to evaluate long-term safety and effectiveness of the drug on a large, heterogenous population.An online expert meeting was held from March 20 to March 30, 2023, which provided relevant insights into the decision-making process regarding seton use and obtained feedback on the first experiences with darvadstrocel. The aim of this article is to present the perspectives from gastroenterologists and colorectal surgeons practicing in Czechia, Hungary, Israel, Lithuania, Serbia, and Slovenia in topics such as diagnosis and treatment options for patients with complex Crohn's perianal fistulas (CPF), specifically focusing on the use of setons and darvadstrocel.During this virtual session, unavailability of comprehensive data on safety and efficacy of available treatment procedures was emphasized as an important obstacle towards development of standardized recommendations and improvement of outcomes in treatment of (CPF). Furthermore, achieving consensus in seton use, duration of its placement, and frequency of change is recognized as one of CPF treatments major challenges. Despite these issues, it is important to promote better understanding and treatment of complex perianal fistulas in order to improve the quality of life of those affected by this condition.},
	keywords = {Crohn's disease; Multidisciplinary management; Surgical procedures; Perianal fistulas; long-term safety evaluation; treatment challenges; Darvadstrocel Therapy},
	year = {2024},
	eissn = {1753-6561},
	orcid-numbers = {Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34752035,
	title = {Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system},
	url = {https://m2.mtmt.hu/api/publication/34752035},
	author = {Bacsur, Péter and Wetwittayakhlang, Panu and Resál, Tamás and Földi, Emese and Vasas, Béla and Farkas, Bernadett and Rutka, Mariann and Bessissow, Talat and Afif, Waqqas and Bálint, Anita and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Farkas, Klaudia and Lakatos, Péter László and Molnár, Tamás},
	doi = {10.1177/17562848241239606},
	journal-iso = {THER ADV GASTROENTER},
	journal = {THERAPEUTIC ADVANCES IN GASTROENTEROLOGY},
	volume = {17},
	unique-id = {34752035},
	issn = {1756-283X},
	year = {2024},
	eissn = {1756-2848},
	orcid-numbers = {Bacsur, Péter/0000-0002-8534-0068; Wetwittayakhlang, Panu/0000-0002-5962-4112; Resál, Tamás/0000-0002-3842-9094; Rutka, Mariann/0000-0003-2360-7836; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Lakatos, Péter László/0000-0002-3948-6488; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34741931,
	title = {A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése},
	url = {https://m2.mtmt.hu/api/publication/34741931},
	author = {Miheller, Pál and Kristóf, Tünde and Bor, Renáta and Farkas, Klaudia and Golovics, Petra and Harsányi, László and Müller, Katalin Eszter and Milassin, Ágnes and Palatka, Károly and Schäfer, Eszter and Szamosi, Tamás and Sarlós, Patrícia and Molnár, Tamás},
	doi = {10.1556/650.2024.33050},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {165},
	unique-id = {34741931},
	issn = {0030-6002},
	year = {2024},
	eissn = {1788-6120},
	pages = {37-64},
	orcid-numbers = {Miheller, Pál/0000-0003-3448-4333; Bor, Renáta/0000-0001-9393-5240; Farkas, Klaudia/0000-0003-0599-182X; Harsányi, László/0000-0003-2657-0039; Milassin, Ágnes/0000-0001-6902-8915; Sarlós, Patrícia/0000-0002-5086-9455; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34741930,
	title = {A Crohn-betegég terápiás stratégiája},
	url = {https://m2.mtmt.hu/api/publication/34741930},
	author = {Farkas, Klaudia and Székely, Hajnal and Bacsur, Péter and Bánky, Balázs and Élthes, Zsuzsa Bianka and Harsányi, László and Müllner, Katalin Edit and Milassin, Ágnes and Palatka, Károly and Sarlós, Patrícia and Szamosi, Tamás and Molnár, Tamás and Miheller, Pál},
	doi = {10.1556/650.2024.33020},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {165},
	unique-id = {34741930},
	issn = {0030-6002},
	year = {2024},
	eissn = {1788-6120},
	pages = {1-36},
	orcid-numbers = {Farkas, Klaudia/0000-0003-0599-182X; Bacsur, Péter/0000-0002-8534-0068; Bánky, Balázs/0000-0002-4297-9072; Harsányi, László/0000-0003-2657-0039; Müllner, Katalin Edit/0000-0001-8081-9515; Milassin, Ágnes/0000-0001-6902-8915; Sarlós, Patrícia/0000-0002-5086-9455; Molnár, Tamás/0000-0002-4913-7599; Miheller, Pál/0000-0003-3448-4333}
}

@article{MTMT:34635367,
	title = {Szűrő kolonoszkópos vizsgálatok hatékonyságának és biztonságosságának értékelése a Szegedi Tudományegyetemen és a Bács-Kiskun Vármegyei Oktatókórházban 2019 és 2022 között [Analysis of efficacy and safety of colonoscopic screening program at the University of Szeged and the Bács-Kiskun County Teaching Hospital between 2019 and 2022]},
	url = {https://m2.mtmt.hu/api/publication/34635367},
	author = {Magyar, Dániel and Fábián, Anna and Vasas, Béla and Nacsev, Krisztián and Dubravcsik, Zsolt and Bősze, Zsófia and Tóth, Tibor and Bacsur, Péter and Bálint, Anita and Farkas, Klaudia and Molnár, Tamás and Resál, Tamás and Bor, Renáta and Szepes, Zoltán},
	doi = {10.1556/650.2024.32979},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {165},
	unique-id = {34635367},
	issn = {0030-6002},
	keywords = {colorectal cancer; colorectal adenoma; colorectal carcinoma; Polypectomy; vastagbélrák; colorectal screening program; colorectalis adenoma; colorectalis carcinoma; polypectomia; vastagbélszűrő program},
	year = {2024},
	eissn = {1788-6120},
	pages = {221-231},
	orcid-numbers = {Fábián, Anna/0000-0002-0824-7476; Bacsur, Péter/0000-0002-8534-0068; Bálint, Anita/0000-0002-3624-896X; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599; Resál, Tamás/0000-0002-3842-9094; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719}
}

@article{MTMT:34558117,
	title = {Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics. a multicenter observational study},
	url = {https://m2.mtmt.hu/api/publication/34558117},
	author = {Dragoni, Gabriele and Innocenti, Tommaso and Amiot, Aurelién and Castiglione, Fabiana and Melotti, Laura and Festa, Stefano and Savarino, Edoardo Vincenzo and Truyens, Marie and Argyriou, Konstantinos and Noviello, Daniele and Molnár, Tamás and Bouillon, Vincent and Bezzio, Cristina and Eder, Piotr and Fernandes, Samuel and Kagramanova, Anna and Armuzzi, Alessandro and Oliveira, Raquel and Viola, Anna and Ribaldone, Davide Giuseppe and Drygiannakis, Ioannis and Viganò, Chiara and Calella, Francesca and Gravina, Antonietta Gerarda and Pugliese, Daniela and Chaparro, María and Ellul, Pierre and Vieujean, Sophie and Milla, Monica and Caprioli, Flavio},
	doi = {10.14309/ajg.0000000000002676},
	journal-iso = {AM J GASTROENTEROL},
	journal = {AMERICAN JOURNAL OF GASTROENTEROLOGY},
	unique-id = {34558117},
	issn = {0002-9270},
	abstract = {Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of post-operative complications of tofacitinib exposure before colectomy in comparison with biologics.A multicentre, retrospective, observational study was conducted in patients with UC who underwent total colectomy for medically refractory disease, exposed to tofacitinib or a biologic before surgery. Primary outcome was the occurrence of any complication within 30 (early) and 90 (late) days after surgery. Secondary outcomes were the occurrence of infections, sepsis, surgical site complications, venous thromboembolic events (VTE), hospital re-admissions, and redo surgery within the same timepoints.Three hundred and one patients (64 tofacitinib, 162 anti-TNFs, 54 vedolizumab, 21 ustekinumab) were included. No significant differences were reported in any outcome, except for a higher rate of early VTE with anti-TNFs (P=0.047) and of late VTE with vedolizumab (P=0.03). In the multivariate analysis, drug class was not associated with a higher risk of any early and late complications. Urgent colectomy increased the risk of any early (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.06-3.48) complications, early hospital re-admission (OR 4.79, 95%CI 1.12-20.58), and early redo surgery (OR 7.49, 95%CI 1.17-47.85). A high steroid dose increased the risk of any early complications (OR 1.96, 95%CI 1.08-3.57), early surgical site complications (OR 2.03, 95%CI 1.01-4.09), and early redo surgery (OR 7.52, 95%CI 1.42-39.82). Laparoscopic surgery decreased the risk of any early complications (OR 0.54, 95%CI 0.29-1.00), early infections (OR 0.39, 95%CI 0.18-0.85), and late hospital re-admissions (OR 0.34, 95%CI 0.12-1.00).Pre-operative tofacitinib treatment demonstrated a post-operative safety profile comparable to biologics in patients with UC undergoing colectomy.},
	year = {2024},
	eissn = {1572-0241},
	orcid-numbers = {Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34546005,
	title = {P938 Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases – prospective, cohort study},
	url = {https://m2.mtmt.hu/api/publication/34546005},
	author = {Resál, Tamás and Bacsur, Péter and Pápista, M and Kata, D and Farkas, Bernadett and Bálint, Anita and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Farkas, Klaudia and Molnár, Tamás},
	doi = {10.1093/ecco-jcc/jjad212.1068},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34546005},
	issn = {1873-9946},
	year = {2024},
	eissn = {1876-4479},
	pages = {i1706-i1707},
	orcid-numbers = {Resál, Tamás/0000-0002-3842-9094; Bacsur, Péter/0000-0002-8534-0068; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34538619,
	title = {P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment},
	url = {https://m2.mtmt.hu/api/publication/34538619},
	author = {Bacsur, Péter and Resál, Tamás and Farkas, Bernadett and Sarlós, P and Iliás, Á and Kata, Diána and Bálint, Anita and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Molnár, Tamás and Farkas, Klaudia},
	doi = {10.1093/ecco-jcc/jjad212.0804},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34538619},
	issn = {1873-9946},
	year = {2024},
	eissn = {1876-4479},
	pages = {i1279-i1280},
	orcid-numbers = {Bacsur, Péter/0000-0002-8534-0068; Resál, Tamás/0000-0002-3842-9094; Kata, Diána/0000-0002-4432-9380; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Molnár, Tamás/0000-0002-4913-7599; Farkas, Klaudia/0000-0003-0599-182X}
}